Tests NMD670 at 3 dose levels in adults with myasthenia gravis
Tests 3 doses of NMD670 against placebo in adults with myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Key facts
- Where
- Augusta, Aurora, Boca Raton, Carlsbad, Chapel Hill, Columbia, Columbus, Irvine, Memphis, Portland, and Tampa, United StatesSee the 11 sites
- Phase
- Phase 2
Where in United States
- Augusta University-Neuroscience CenterAugusta, United StatesTaking people
- University of Colorado Neuromuscular DivisionAurora, United StatesTaking people
- SFM Clinical Research LLCBoca Raton, United StatesTaking people
- Profound Research LLCCarlsbad, United StatesNo longer taking part
- The University of North Carolina at Chapel HillChapel Hill, United StatesTaking people
- NextGen Precision HealthColumbia, United StatesTaking people
- The Ohio State UniversityColumbus, United StatesTaking people
- University of California, Irvine Medical CenterIrvine, United StatesTaking people
- Semmes Murphey ClinicMemphis, United StatesNo longer taking part
- University of OregonPortland, United StatesTaking people
- Neuromuscular Research Division | University of South FloridaTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NMD Pharma A/S
- Trial code
- NCT06414954
- Record updated
- 21 August 2026
- Original description
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.Read full original descriptionShow less
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Inclusion: Participant must be a male or female being 18 or more, at the time of signing the informed consent; Diagnosis of MG, MGFA class II, III or IV; Documented positive AChR or MuSK antibody test; Participant must be able to swallow tablets; Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg; Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; Participant is capable of and has given signed informed consent.
Exclusion: Participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to Day 1; Known medical or psychological condition(s) or risk factor that, in the opinion of the Investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study; Participants with history of poor compliance with relevant MG therapy; Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study; Female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding.